JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole
AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) …
Post
-
-
Zai Labs announces positive results in China arm of Phase III cervical cancer trial
Chinese-American biopharmaceutical company Zai Lab has announced positive topline results from the China-specific arm in its Phase III innovaTV-301 study …
-
JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline
Bruce Cozadd, the retiring CEO of Jazz Pharmaceuticals, has outlined a developing oncology pipeline at the company. Speaking at the JP …
-
Volunteering decreases odds of depression in community dwellers
Depression is a common but complex condition. GlobalData epidemiologists estimate there will be 27.8 million 12-month total prevalent cases of …
-
Context doses first subject in Phase I cancer trial of CTIM-76
Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting claudin 6 (CLDN6)-positive gynaecologic and …
-
Sling Therapeutics sees success reducing eye bulge in Phase IIb/III trial
Michigan late-stage biopharma, Sling Therapeutics, said a Phase IIb/III LIDS trial of its oral small molecule therapy designed to treat …
-
WHO reports eight deaths from suspected Marburg outbreak in Tanzania
Eight people have likely died from an outbreak of Marburg virus disease (MVD) in a northwestern region of Tanzania, according …
-
Pheno Therapeutics gains UK MHRA’s CTA for multiple sclerosis therapy trial
Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its …
-
How a Fresh Approach to Supply Chains Can Unlock Scaling in Personalized Medicine
Precision medicine represents a new frontier in healthcare. By stratifying patients based on genomic and phenotypic variations, it addresses the …
-
Herd immunity hurdles: The consequences of declining vaccine coverage
In recent years, paediatric immunisation rates in the US have been declining. Vaccines have long been a cornerstone of public …
-
Vistagen reports positive outcomes from Phase IIA cancer cachexia trial
Vistagen has reported positive outcomes from the exploratory Phase IIA trial of an investigational pherine nasal spray, PH284, for the …
-
Alleviant Medical secures $90m to launch pivotal aortic stent trial
Texas medical device firm Alleviant Medical has secured $90m to fund a second pivotal trial of the company’s heart system …
-
JP Morgan 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance
Moderna lost more than 20% of its value on the stock market as the company delivered slashed revenue guidance for …
-
Clinical research survey results: The key pressures for SMEs and business outlook
The pharma sector is at a crossroads, with major challenges for small and medium-sized businesses driving clinical research. However, there …
-
As avian influenza A(H5N1) concerns continue, mRNA vaccines offer great potential
With cases of avian influenza A(H5N1) continuing to rise among cattle and humans in the US, scientists and government health …
